/ Print /

Pharmacy Best Practices

Study: New cholesterol drugs cost 356 times more than genericsA report from the Alliance of Community Health Plans can help get a better sense of how well drugs help patients compared to other treatment options.
How the presidential candidates plan to rein in pharma costs
How the presidential candidates plan to rein in pharma costsFind out where each presidential candidate stands on key issues related to pharmaceutical costs.
Managed care pharmacy survey findings 2016To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive, in partnership with Access Market Intelligence and the National Institute of Collaborative Healthcare, conducted its first-ever pharmacy survey during the second quarter of 2016.
HHS makes clinical trials more transparentHHS finalized ClinicalTrial.gov rules encourage healthcare improvement and public benefit by increasing transparency and accountability across the industry.
Medicare Part D patients not taking blood pressure meds correctlyExpert offers specific actions for managed care execs to take
Providers are failing to meet needs of depressed patientsA new study shows that many adults with depression don’t receive treatment, whereas others receive treatments that do not match their level of illness severity.
Insurer expands hep C drug coverageNationwide class action suit spurs new coverage decision for hepatitis C medications.
Don't overlook vaccines in value-based benefit designA new study highlights why vaccination costs should be a top consideration when evaluating benefit offerings.
Integrated pharmacy model improves adherence, reduces costsStudy shows that an integrated pharmacy approach with community mental health centers produces higher adherence rates and lower overall healthcare costs.
Predictions for biosimilars: How market access will play outEarly planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.